Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.08, $0.31 better than the analyst estimate of $3.77. Revenue for the quarter came in at $2.47 billion versus the consensus estimate of $2.43 billion.

GUIDANCE:

Biogen sees FY2024 EPS of $16.10-$16.60, versus the consensus of $16.19.

For earnings history and earnings-related data on Biogen (BIIB) click here.